Aspivix: Redefining Women’s Healthcare
Every year, millions of women avoid intrauterine devices (IUDs), despite being more than 99% effective — because of the pain associated with current placement techniques. This contributes to approximately 121 million unintended pregnancies annually, with major personal, medical and societal consequences.
Aspivix is transforming this experience with carevix®, a modern, non-traumatic device designed to replace the outdated cervical tenaculum — a sharp, clamp-like instrument still routinely used to stabilize the cervix during gynecological procedures. Using gentle suction instead of traumatic hooks, carevix® significantly improves the patient experience while maintaining the safety, precision and reliability required by healthcare professionals.
Why Invest in Aspivix?
1. Regulatory Excellence
carevix® is FDA-cleared in the United States, CE Mark-approved under MDR, and authorized in the UK, Switzerland and Brazil, enabling rapid international deployment.
2. Strong Clinical Validation
- 73% reduction in pain
- 83% reduction in bleeding
- Clinical benefits demonstrated in a randomized controlled trial (RCT)
- More than 1,300 procedures documented through large real-world evidence (RWE) programs across 9 countries
3. Clear Market Need
More than 30% of women avoid IUDs because of fear of pain. carevix® directly addresses this barrier and supports access to one of the world’s most effective contraceptive methods.
Hear it from one of our investors:
4. Commercial Momentum
carevix® is now commercialized in the US and 13 countries globally, with commercial launch underway in Germany and strong early traction in Switzerland, including approximately 10% market penetration and more than 21% repeat customers within a short timeframe. Revenue generated mainly from Switzerland and the Netherlands reached nearly USD 330k in 2025 and target USD 1.5M in 2026.
Hear it from one of our investors:
5. Strategic Validation
A collaboration, in 2 countries, with Bayer, the global leader in women’s health and IUDs, reinforces the strategic relevance and commercial potential of carevix®.
6. Sustainability
Aspivix is actively reducing its environmental footprint and developing next-generation products integrating bio-sourced materials and more sustainable manufacturing approaches.
Series B2 Positioning
This financing round represents the natural continuation of Aspivix’s successful Series B1 conducted in 2024–2025, which enabled the company to transition from early clinical validation to a substantially strengthened evidence base and initial commercial traction.
Since then, Aspivix has expanded its scientific leadership through multiple new studies and two major RWE publications in BMJ Sexual & Reproductive Health and the International Journal of Gynecology & Obstetrics in 2025. The company has simultaneously strengthened its regulatory position, broadened clinical indications, and accelerated international commercialization.
The objective of Series B2 is clear:
- accelerate commercial growth, and reach key value inflection points, including $1.5M annual revenue
- reinforce strategic partnerships,
- expand clinical adoption, including new fertility-related indications, by enrolling first patient into fertility related clinical studies (Hyfosy & IUI),
- and reach key value inflection points in R&D, including the FDA submission/clearance of carevix evo.
These milestones are expected to position Aspivix for either a major financing round or a strategic acquisition opportunity.
Supported by a highly experienced team, growing international traction, strong operational readiness and a technology recognized among TIME Magazine’s Best Inventions of 2024, Aspivix combines strong societal impact, global scalability, and the potential for attractive investor returns in a rapidly growing women’s health market.
By investing in Aspivix, you’re contributing to a future where women have better access to gentle, effective contraceptive solutions. Together, we can empower millions and make a lasting social impact while driving meaningful returns.
Join us in making a difference.
